Skip to content

Exelixis EXEL Price / earnings

Price / earnings at other companies

Eli Lilly logo
Eli LillyLLY
32.5×-34.3×
Pfizer logo
PfizerPFE
14.7×
Incyte logo
IncyteINCY
13.1×-538×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
19.8×-16.3×
ALN
Alnylam PharmaceuticalsALNY
87.4×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
15.6×-7.1×

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Calculated from Exelixis’s reported figures.

Based on the most recent quarter.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's price / earnings?
Exelixis (EXEL) reported price / earnings of 13.6× in Q1 2026.
How has Exelixis's price / earnings changed year-over-year?
Exelixis's price / earnings decreased by 15.0% year-over-year, from 15.9× to 13.6×.
What is the long-term trend for Exelixis's price / earnings?
Over 4 years (2020 to 2025), Exelixis's price / earnings has grown at a -31.1% compound annual growth rate (CAGR), from 62.9× to 14.2×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.